Discovery of a small molecule TLR3 agonist adjuvant
Open Access
- 4 December 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Pattern-recognition receptor (PRR) agonists are valuable agents across multiple medical applications, from vaccinology to immune-oncology. However, well-defined and potent small molecule agonists for many PRRs still await discovery and development. Screening of chemical libraries of ~200,000 small molecules for maturation of human monocytic cells by quantifying NF-κB activation and cell adherence was completed. From this screen, we selected a thiazole benzamide derivative, PVP-057, for its robust immunomodulatory properties, low toxicity profile, and concentration-dependent activity. In vitro investigation of pathway and receptor activation reveals that PVP-057 is a Toll-like receptor 3 (TLR3) agonist. As a single-component adjuvant, administered intramuscularly or intradermally to female mice, PVP-057 enhances long-term humoral immunogenicity of varicella-zoster virus glycoprotein E to levels comparable to those induced by the clinical grade standard benchmark adjuvant, AS01B, while concurrently inducing cell-mediated immunity. To demonstrate the large-scale and precise synthesis necessary for the efficient mass production of a small molecule agonist, a green chemistry approach was completed, devising a three-step, 24-hour synthesis scheme for PVP-057, with a reliable purity of ~98%. Featuring highly efficient and scalable synthesis, a distinct TLR3-dependent mechanism of action, and robust adjuvanticity, the PVP-057 pharmacophore has prophylactic and therapeutic potential.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400052C)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C00044)
This publication has 68 references indexed in Scilit:
- OMIP‐111: Immune‐Profiling of T Helper 1 (Th1), Th2, and Th17 Signatures in Murine Splenocytes by Targeting Intracellular CytokinesCytometry Part A, 2025
- An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicityCell, 2022
- TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative reviewImmunologic Research, 2021
- Biologics vs. small molecules: Drug costs and patient accessMedicine in Drug Discovery, 2021
- Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responsesJournal of Allergy and Clinical Immunology, 2017
- Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine ImmunityEBioMedicine, 2016
- Introduction to Costimulation and Costimulatory Molecules2015
- TLR3 immunity to infection in mice and humansCurrent Opinion in Immunology, 2013
- Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: Key regulators of innate immunityPharmacology & Therapeutics, 2009
- A comparative analysis of cytokine responses, cell surface marker expression and MAPKs in DCs matured with LPS compared with a panel of TLR ligandsCytokine, 2008